Current:Home > reviewsThe FDA is weighing whether to approve MDMA for PTSD. Here's what that could look like for patients. -ProsperityStream Academy
The FDA is weighing whether to approve MDMA for PTSD. Here's what that could look like for patients.
View
Date:2025-04-24 10:51:05
Ahead of a key meeting Tuesday to weigh the potential approval of midomafetamine, or MDMA, for patients with post-traumatic stress disorder, the Food and Drug Administration is proposing a new set of restrictions on how eligible patients would be able to get the drug.
Details of the FDA's proposal were published Friday in a set of documents released by the agency ahead of an advisory committee meeting next week.
After the panel votes, drugmaker Lykos Therapeutics says the FDA is expected to make a decision by Aug. 11 on whether to approve its approach for patients with PTSD: a four-month course of MDMA combined with psychotherapy.
Among the FDA's questions for the committee is whether the benefits of MDMA, combined with the FDA's proposed restrictions on prescriptions for the hallucinogenic drug, will be enough to outweigh its risks.
"Patient impairment is an expected effect from midomafetamine administration and there must be safeguards to mitigate serious harm from patient impairment, similar to the risk mitigation in the clinical trials, to support patient safety," the FDA's reviewers said in a briefing document ahead of the meeting.
Under the proposal, administering MDMA would be restricted to healthcare facilities that agree to ensure at least two providers are onsite to monitor patients while taking the drug.
Patients will need to be monitored for at least eight hours, until they are psychologically stable enough to be discharged to an adult after the session. During the trials, many ended up staying overnight at study sites, being monitored by therapists.
Providers will also need to prepare for some physical risks. In the trials, one participant was hospitalized after MDMA was suspected to have exacerbated a pre-existing heart problem.
Patients will also need to be enrolled in a registry tracking side effects and issues that come up from the sessions, as well as how they are faring following completion of the treatment.
"We are also concerned about worsening of psychological disorders that cause disability or that may lead to hospitalization or death, and suicidal behaviors and ideation," the FDA said.
The drugmaker has also been in talks with the FDA over other steps to curb risks of the drug, like providing the product in only single dose packages aimed at limiting the risk of "nonmedical use," Lykos said in their briefing document.
The FDA often turns to its authority to apply additional restrictions on prescription drugs, dubbed Risk Evaluation and Mitigation Strategies or REMS, to curb the pitfalls of drugs that it thinks would otherwise be too dangerous to approve.
Nasal sprays of hallucinogen esketamine to treat depression, branded as Spravato, were also approved in 2019 under these kinds of REMS restrictions.
Additional restrictions could be imposed by a different agency – the Drug Enforcement Administration – which will be responsible for "rescheduling" the drug.
The DEA currently deems MDMA or "ecstasy" to be a Schedule I drug, alongside other substances like heroin which the DEA says have "no currently accepted medical use and a high potential for abuse."
Alexander TinAlexander Tin is a digital reporter for CBS News based in the Washington, D.C. bureau. He covers the Biden administration's public health agencies, including the federal response to infectious disease outbreaks like COVID-19.
TwitterveryGood! (4829)
Related
- Nearly 400 USAID contract employees laid off in wake of Trump's 'stop work' order
- 'Gen V', Amazon's superhero college spinoff of 'The Boys,' fails to get a passing grade
- Spanish griffon vultures are released into the wild in Cyprus to replenish the dwindling population
- Hundreds of thousands of workers may be impacted by furloughs if government shutdown occurs
- Bill Belichick's salary at North Carolina: School releases football coach's contract details
- Blake Shelton Reveals the Epic Diss Toby Keith Once Gave Him on Tour
- Oxford High School shooter will get life in prison, no parole, for killing 4 students, judge rules
- Guitarist Al Di Meola suffers heart attack on stage while performing but is now in stable condition
- The Daily Money: Spending more on holiday travel?
- AP Week in Pictures: Asia
Ranking
- Could your smelly farts help science?
- Dozens dead after blast in southwestern Pakistan at a rally celebrating birthday of Islam’s prophet
- Afghan embassy says it is stopping operations in Indian capital
- Remains found of Colorado woman Suzanne Morphew, who went missing on Mother’s Day 2020
- Rylee Arnold Shares a Long
- AP Week in Pictures: Asia
- Daniel Radcliffe breaks silence on 'Harry Potter' Dumbledore actor Michael Gambon's death
- Trump won’t try to move Georgia case to federal court after judge rejected similar bid by Meadows
Recommendation
Pregnant Kylie Kelce Shares Hilarious Question Her Daughter Asked Jason Kelce Amid Rising Fame
The White House chief of staff says it's on House Republicans to avert a shutdown
Did this couple predict Kelce-Swift romance? Halloween costume from 2020 goes viral
8 Jaw-Dropping Sales You Don't Want to Miss This Weekend: J.Crew Factory, Elemis, Kate Spade & More
The Grammy nominee you need to hear: Esperanza Spalding
The White House chief of staff says it's on House Republicans to avert a shutdown
Seattle cop who made callous remarks after Indian woman’s death has been administratively reassigned
Remote work: Is it time to return to the office? : 5 Things podcast